Since its discovery as an important regulator of fuel utilization in the periphery, AMP-activated protein kinase (AMPK) has become a contender for many important cell-intrinsic and organismal roles regarding energy balance in the central nervous system. The challenge will be to delineate the mechanisms by which neuronal AMPK can respond to cellular energy requirements as well as whole body energy demands. Thus, under physiological conditions in the brain, hypothalamic AMPK responds to changes in energy balance/food intake, whereas under pathological conditions, AMPK responds globally in the brain to energy challenge. Modulation of fatty acid metabolism affects energy balance in a context-specific manner and may provide an insight into other mechanisms for selective activation or inhibition of AMPK activity for therapeutic applications.
Introduction
Many diseases result from metabolic dysregulation or, more specifically, energy dysregulation. As a prime example, obesity, now epidemic in developed nations, may be viewed as disordered energy balance occurring when energy intake exceeds energy expenditure. The past decade has seen impressive growth in our understanding of the physiological regulation of energy balance and adiposity, notably from the discovery of the adiposity hormone leptin and subsequent identification of hypothalamic and other brain neuropeptide systems controlling energy balance. 1 The list of central nervous system (CNS) and peripheral players in energy homeostasis has grown tremendously, so it would seem that there are numerous options for targeted therapy. Yet despite the advances, effective therapies for obesity remain elusive. Targeting any one of the CNS or peripheral modulators of energy balance often presents the problem of being surmountable by other systems left intact, so that weight loss is temporary. Although multifaceted approaches may prove helpful for antiobesity treatments, another powerful option now lies before us: targeting the very molecules most fundamental for energy balance. AMP-activated protein kinase (AMPK) is a cellular and organismal energy and stress sensor that promotes the activation of energy restorative (catabolic) processes and inhibition of energy consumptive (anabolic) processes. 2, 3 We and other laboratories have shown that hypothalamic AMPK plays a major role in the regulation of organism's energy balance. [4] [5] [6] Our interest in hypothalamic AMPK grew from our work with C75, a synthetic molecule that inhibits fatty acid synthase (FAS) 7 and stimulates carnitine palmitoyltransferase-1 (CPT-1) and beta-oxidation of fatty acids. [8] [9] [10] Fatty acid metabolic pathways are poised at a crossroads of energy deficit and energy surplus, with the potential to either use or make the high-energy molecule ATP. We have shown that C75 increases cellular ATP, and decreases the phosphorylation status and activity of AMPK. 4, 8 By increasing the local energy level in energy-sensing hypothalamic neurons, C75 elicits mechanisms that decrease the organism's energy intake and likely also serve to increase wholebody energy expenditure. In our other work, we have also determined that C75 is neuroprotective. By decreasing the activity of AMPK in the brain, C75 dramatically reduces the brain tissue damage resulting from ischemia. 11 Thus, the strategy provides context-specific health benefits. Our studies speak about the utility of pharmacological manipulations of brain AMPK activity for restoring or maintaining brain and organism's health.
Metabolism and AMPK
Fatty acid metabolism, ATP and C75 Synthesis of fatty acids increases when energy is in surplus to produce triglycerides for storage. Conversely, during periods of energy deficiency, fatty acid synthesis is reduced and triglycerides are oxidized to generate energy. FAS is the enzyme responsible for de novo synthesis of fatty acids. Mammalian FAS contains seven distinct enzyme activities on a single B250 kDa polypeptide that is modified posttranslationally with a phosphopantotheine 'arm' to tether the growing acyl chain as it moves through the seven enzyme activities. FAS requires NADPH to condense one acetyl-CoA with seven malonyl-CoAs, each of which are also derived from acetyl-CoA in an ATP-dependent reaction catalyzed by acetyl-CoA carboxylase (ACC). [12] [13] [14] Thus, palmitate synthesis is energy-dependent, utilizing 7 ATP and 14 NADPH per molecule of palmitate generated. Malonyl-CoA can be degraded back to acetyl-CoA by malonyl-CoA decarboxylase. 15 FAS is regulated transcriptionally. 13 In the periphery, FAS message is present when energy levels are high, and is rapidly downregulated during times of energy depletion when stored fat is mobilized for fuel. Although both FAS and ACC are regulated transcriptionally, ACC is the rate-limiting enzyme regulated rapidly during times of energy fluctuation by phosphorylation. ACC activity is increased by citrate, insulin and ATP, and is decreased by palmitoyl-CoA, glucagon and AMPK. [16] [17] [18] Mammals have two isoforms of ACC, each encoded by different genes and distributed in distinct tissues. 16, 19 ACCa is mainly expressed in the liver and adipose tissue, whereas ACCb is highly expressed in the heart and muscle. Malonyl-CoA, the substrate for FAS, is also a competitive inhibitor of CPT-1, located in the outer mitochondrial membrane and rate-limiting for entry of long-chain acyl-CoAs into mitochondria for b-oxidation. 20, 21 The rate of fatty acid synthesis increases during energy surplus, and the resulting elevated steady-state levels of malonyl-CoA inhibit CPT-1 to prevent oxidation of the newly synthesized fatty acids. CPT-1 has three isoforms. L-CPT-1 (liver form/CPT-1a) is expressed in most tissues, including the liver, kidney, lung and heart. 22, 23 M-CPT-1 (muscle form/CPT-1b) is expressed in the skeletal muscle, heart and adipose tissue. 22, 24 CPT-1C (CPT-1g) is a recently reported brain-specific isoform of unclear activity.
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The a-methylene-g-butyrolacetone C75 was designed to interfere with the activity of the b-ketoacyl synthase of mammalian FAS. The b-ketoacyl synthase covalently joins acetate and malonate together. Thus, C75 prevents elongation of the acyl chain.
7 C75 reduces fatty acid synthesis in every tissue and cell type tested so far (liver, white fat, bone, carcinoma and neuron). [7] [8] [9] [10] 26 C75 also competes with malonyl-CoA, thus increasing CPT-1 activity. [8] [9] [10] C75 potently increases fatty acid oxidation and ATP levels in vitro 8, 10, 26 by increasing CPT-1 activity (CPT-1s), even in the presence of elevated, inhibitory concentrations of malonyl-CoA.
AMP-activated protein kinase AMPK is a member of a metabolite-sensing kinase family. 2, 3 AMPK is a heterotrimeric serine/threonine kinase composed of a catalytic a subunit and regulatory b and g subunits. 27, 28 There are isoforms of a (a1 and a2), 29 and of b (b1 and b2) 29 and g subunits (g1, g2 and g3). 30 Depending on the tissue, cell type and subcellular localization, varying combinations of abg heterotrimers are possible and may explain AMPK's diverse biological effects. 3, 31 AMPK is activated by AMP binding to the g subunit, facilitating phosphorylation of the a subunit on T172 by an upstream kinase. There is also evidence for allosteric and catalytic sites for ATP on AMPK, suggesting that high levels of ATP might inhibit AMPK directly. AMPK is activated by depleted cellular ATP (or increased AMP/ATP) and also by drugs, hormones, and osmotic, oxidative and nitrosative stresses that do not alter AMP/ATP. When activated, AMPK inhibits ATP-using (anabolic) processes and stimulates ATP-making (catabolic) processes. 32, 33 Consequences of AMPK activation encompass acute modulation of energy metabolism and chronic changes in gene expression to enhance cellular survival under stressful, energy-demanding conditions. 34, 35 AMPK is best known as a metabolic sensor in peripheral tissues such as cardiac and skeletal muscle, liver, adipose tissue and pancreas. 2, 31 Hormones and pharmacological agents modulate AMPK activity in muscle, liver and hypothalamus to promote fatty acid oxidation, glucose utilization and feeding responses. [4] [5] [6] 36, 37 Physiological stimuli can activate AMPK to promote tissue-specific responses such as skeletal muscle glucose uptake and glycolysis through glucose transporter translocation and 6-phosphofructo-2-kinase kinase activity, respectively, and fatty acid oxidation. 32, 33, 38 Liver AMPK inhibits fatty acid and cholesterol biosynthesis by phosphorylating and inactivating ACC and 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
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Hypothalamic AMPK and regulation of energy balance AMPK is now recognized to participate in energy-sensing in the hypothalamus, 4-6 as reviewed herein. Our interest in hypothalamic AMPK grew from our work with C75. General brain injection of C75 in rodents decreases food intake and body weight, 4, 26, 40, 41 so C75 exerts some of its weight loss effects by acting in CNS. Once we knew that C75 altered pAMPK in neurons in vitro, 8 we altered the brain and hypothalamic AMPK in mice using well-known pharmacological tools, and fed and fasted states, to demonstrate that AMPK was a physiological mediator of C75's effects. 4 Other research groups also altered hypothalamic AMPK activity using genetic approaches 5 or peripheral hormones 5, 6 to alter hypothalamic AMPK activity. These studies suggest that hypothalamic AMPK controls energy expenditure and fuel utilization as well. The emerging model is one with hypothalamic AMPK as a master controller of organism energy balance. Collectively, the data make the case that hypothalamic AMPK is a molecule with broad physiological importance for the control of food intake.
C75: food intake, body weight and hypothalamic neuropeptide signaling effects
In the initial report, peripheral administration of C75 caused rapid and profound anorexia and reversible weight loss.
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C75 alleviated fatty liver seen in obese mice 9, 26 and selectively reduced adipose mass. 9 Inhibition of peripheral fatty acid synthesis and stimulation of fatty acid oxidation could explain some of these effects. However, C75 also decreased feeding and body weight when administered into the brain by intracerebroventricular (i.c.v.) injection, 4, 26, 40, 41 at doses considerably lower than effective peripheral doses, suggesting that C75 interacted directly with the brain to alter food intake. Although high doses of peripherally injected C75 produced conditioned taste aversion and other indices of malaise in rats, 42, 43 C75 given i.c.v. reduces rats' food intake without eliciting conditioned taste aversion. 42 C75
does not produce conditioned taste aversion in mice. 44 Central C75's lack of untoward effects indicates that it acts in the brain to mediate hypophagia more specifically related to energy balance. C75's hypophagic and weight loss effects were considered to be independent of or downstream of leptin action, because ob/ob mice (leptin deficient) and db/db mice (functional leptin receptor deficient) responded to C75. 26 The initial results prompted us and others to identify mechanisms by which C75 could reduce energy intake. C75 changes brain neuronal activation 45 and gene expression of hypothalamic neuropeptides that are pivotal in regulating food intake and energy balance. 4, 26, 46, 47 Data suggesting that many of these changes with C75 could stem from cell-autonomous mechanisms in neurons of the hypothalamus came from our work. FAS and other enzymes involved in fatty acid metabolism were expressed in neurons in the brain, particularly in hypothalamic nuclei involved in the regulation of energy balance. 44 The hypothalamus integrates signals of nutrient, hormone and neural input of energy status from the extracellular environment, other brain regions and peripheral tissues, and then coordinates CNS and peripheral tissue mechanisms that defend energy homeostasis. In a simplified model, the arcuate nucleus (ARC) is viewed as the main signal receiver in the hypothalamus. 1 The ARC contains two neuron types with leptin and insulin receptors. The lateral ARC contains neurons that make proopiomelanocortin, a precursor of anorexigenic a-melanocyte-stimulating hormone, 48 an agonist at melanocortin-3 and melanocortin-4 receptors. a-Melanocyte-stimulating hormone 49 and synthetic melanocortin agonists reduce feeding, 50 and food deprivation decreases and overconsumption increases proopiomelanocortin. 51 reductions in feeding might be thus coordinated with reductions in water intake). C75 partly prevented c-Fos expression in a third medial ARC target, the dorsomedial hypothalamus, containing NPY and orexin-A. 56, 59 Importantly, C75 increased c-Fos in parvocellular paraventricular nucleus (containing the anorexigenic neuropeptides CRH, TRH and oxytocin [60] [61] [62] ), consistent with our earlier study in which C75 increased mRNAs for CRH and oxytocin (but not TRH). 44 
Neuronal mechanisms of C75 action: ATP and AMPK
To determine the feasibility of further investigating C75's effects on energy-related processes in hypothalamic neurons, we looked at the effects of C75 in a primary neuronal culture system already in use in our laboratory. Primary cultures of rat cortical neurons contain FAS. 8 C75 dose-dependently decreased acetate incorporation into lipids (an estimate of FAS activity), and increased the formation of acyl-carnitine (indicating increased CPT-1 activity). Although fatty acid oxidation is limited in neurons, 63 C75 increased b-oxidation to 150% of control in primary cultures. C75 also increased glucose oxidation. As predicted from these actions of cell metabolism, C75 also increased ATP levels in the neuron cultures. Interestingly, C75 produced a biphasic alteration in neuronal ATP levels. C75 at first decreased ATP levels rapidly to 70% of baseline within 2.5 min, and ATP stayed low for the first 15 min. Then ATP increased gradually until it returned to pre-incubation baseline at 1 h, exceeded it by 50% at 2 h and peaked at 250% of baseline at 8 h. Cells maintain tight regulation of the ratio of phosphorylated and dephosphorylated forms of ATP. 64 The lowest energy form, AMP, is involved in the activation and phosphorylation of AMPK (pAMPK). 2, 3 Consistent with the changes in neuronal ATP levels, C75 increased AMP at the 5 min time point, when ATP was low. C75 altered the levels of pAMPK biphasically, but in opposite directions of those seen with ATP changes, as expected from predicted changes in AMP/ATP ratio. Thus, at 5 min, when ATP was reduced, pAMPK was increased to 125% of baseline. As ATP increased over time, pAMPK levels declined, until at 2 h when they were 25% of control levels. 4 To more closely examine the role of the fatty acid synthetic pathway itself, we looked at ATP and pAMPK changes with the selective FAS inhibitor cerulenin and the ACC inhibitor 5-(tetradecyloxy)-2-furoic acid (TOFA). Cerulenin decreased ATP rapidly, as seen with C75. ATP then gradually returned to baseline by 2 h. However, even increasing the concentration of cerulenin did not raise ATP above baseline. Cerulenin's ability to decrease AMPK activity was not as great as that of C75, as measured in the SAMS peptide assay. Interestingly, cerulenin also seems less effective in inhibiting feeding. 65 The ACC inhibitor TOFA inhibited fatty acid synthesis in the neuron cultures. TOFA did not reduce ATP at early time points, 8 although it did cause impressive increases in ATP at later time points. Despite these high levels of ATP, TOFA did not increase AMPK activity in the SAMS peptide assay. TOFA also did not decrease food intake. 66 FAS inhibition may decrease ATP rapidly through a temporarily continued activity of ATP-dependent ACC, because the end product malonyl-CoA is removed not by FAS, but by malonyl-CoA decarboxylase. This futile cycling of acetyl-CoA could transiently deplete ATP. The rapid drop in ATP after cerulenin and C75, before the rise in ATP, could be important in cerulenin-and C75-induced decreases in feeding. C75-elicited increases in ATP levels in excess of normal baseline may be ascribed to the CPT-1s action of this compound and the resulting increase in b-oxidation. Later, we examined the effects of C75 in primary cultures of hypothalamic neurons. Hypothalamic neurons, like cortical neurons, 8 contain FAS, 44 so hypothalamic neurons can respond to C75. C75 changed ATP levels in hypothalamic neurons, as it did in cortical neurons; ATP increased to 118% after 30 min incubation and to 128% at 2 h. Consistent with increased ATP in the hypothalamus, C75 reduced pAMPK in the hypothalamus. 4 Role for hypothalamic AMPK in the control of food intake
We hypothesized that, as in peripheral tissues, AMPK might function as an energy sensor in the hypothalamus, and that C75 exerted its effects on food intake and body weight by affecting the activity of hypothalamic AMPK. 16 To examine the effects of dynamic changes of AMPK activity, not possible with genetic manipulations, we determined the effects of pharmacological inhibition of AMPK using Compound C, 67 or activation of AMPK using the AMP-mimetic AICAR 68 administered into the lateral ventricle 4 on food intake and body weight. Thus, we found that the AMPK inhibitor Compound C, like C75, decreased feeding and body weight, whereas AICAR increased food intake. Our results are consistent with those of Minokoshi et al., who injected the mediobasal hypothalamus with adenoviruses expressing constitutively active AMPK or dominant-negative AMPK. 5 Consistent with our AICAR data, constitutively active AMPK mice ate more and gained more weight than controls, and consistent with Compound C results, dominant-negative AMPK mice ate less, lost more weight after surgery and regained weight more slowly than controls. 5 Collectively, our data and those of Minokoshi et al. indicate that alterations in hypothalamic AMPK activity are sufficient to drive feeding changes. Furthermore, unlike in muscle, where positive body energy status increases AMPK activity, in the hypothalamus AMPK activity is increased when body energy status is low. Thus, we found that fasting for 24 h decreased hypothalamic pAMPK. 4 Hypophagia-inducing doses of i.c.v.
C75, like Compound C, decreased pAMPK levels in lysates of whole hypothalamus. This effect was both rapid and persistent. C75 decreased hypothalamic pAMPK at 3 h after injection, whereas fasting-induced decreases in pAMPK were not seen until 24 h. Consistent with the decreased pAMPK, i.c.v. C75 increased ATP levels in whole hypothalamus. Consistent with whole hypothalamus, i.c.v. C75 decreased pAMPK in ARC at 24 h. 4 Minokoshi et al. showed that positive energy balance from refeeding (after a fast) registered in the hypothalamus as decreased pAMPK when compared with the fasted state. 5 They saw decreased pAMPK in all areas examined (ARC, ventromedial hypothalamus and dorsomedial hypothalamus, paraventricular nucleus, LH). Collectively, the data show that hypothalamic pAMPK level and activity change according to physiological energy state or local hypothalamic simulation of energy states. AICAR given i.c.v. reversed C75-mediated reduction in food intake and decrease in hypothalamic pAMPK.
We have begun to identify intracellular signaling pathways in the ARC that are modulated by altered hypothalamic AMPK activity. Consistent with studies of whole hypothalamus, i.c.v. C75 decreased pAMPK in ARC at 24 h. 4 NPY in ARC was also decreased when compared with fasted levels. NPY suppression was associated with a decreased level of phosphorylated cAMPresponsive binding element, important for gene expression of NPY. 69 We found that NPY and AMPK colocalize in mARC. We used AICAR i.c.v. to increase pAMPK, and found ARC increases in both phosphorylated cAMP-responsive binding element and NPY. 4 Thus, our data suggest that a primary change in AMPK activity modulates an intracellular signaling pathway in conjunction with feeding changes.
C75 and AMPK in other brain areas
In our work with AMPK activity in the control of food intake and body weight, we have focused on the hypothalamus. However, our earlier studies showed that C75 increased ATP, and decreased pAMPK and AMPK activity in cortical neurons cultured in vitro. 8 Could C75 and changes in AMPK activity have effects in the cortex and other brain areas in vivo?
Some work with C75 had raised concerns that C75 was a nonspecific neuronal stimulator 43 and that C75 suppressed feeding by producing nonspecific or untoward effects. 42, 43 For example, C75 increased firing frequency in hypothalamic, cortical and cerebellar neurons in vitro. 43 FAS and CPT-1 are ubiquitous, and any cell that expresses FAS and CPT-1 can respond to C75. In fact, C75 actions on metabolism in a variety of tissues and cell types have shown complete concordance. [7] [8] [9] [10] 26 However, the consequences of these responses are specific to tissue and cell type. The hypothalamus is uniquely poised to sense energy status, and to respond to metabolic challenges to manage whole-body energy balance, but cortical and cerebellar neurons are not. Although one in vitro study found increased neuronal firing in certain brain regions, which might produce seizures and interfere with normal food intake, no laboratories have found that C75 causes seizures. Central C75's lack of untoward effects indicates that it acts in the brain to mediate hypophagia related to energy balance. Moreover, c-Fos changes with C75 were restricted to brain regions involved in the regulation of energy balance (hypothalamus, hindbrain and amygdala) with no c-Fos activation in the cortex or cerebellum. Nevertheless, C75 did increase ATP and decrease pAMPK in cultured neurons from the cortex. 8 The general question of whether C75's general effect in neurons has some relevance for physiology or in pathophysiology is still one of great interest. Under physiological conditions, AMPK plays a role in 'sensing' neuronal energy balance in neurons within the hypothalamus. What is the role of AMPK under extraordinary circumstances?
AMPK and stroke
There are states in which neuronal energy status is threatened and diminished, with devastating results for the organism. In stroke, abnormal brain function results from the disruption of blood flow. The resulting lack of oxygen and glucose incurs excitotoxic and oxidative damage. 70 In the attempt to repair the damage and return neurons to homeostasis, numerous energy-consuming processes are activated. 71 Overactivation of these pathways during ischemia can lead to complete energy failure and cell death. 72 The activation of energy-consuming processes would lead to depleted ATP and increased AMP. Therefore, we hypothesized that AMPK is activated in response to brain energy deficiency. We examined the outcomes of experimentally induced stroke in mice (unilateral middle cerebral artery occlusion, followed by reperfusion) and of oxygen-glucose deprivation in hippocampal slices in vitro. 11 The levels of pAMPK were indeed increased in mouse brain, in neurons (not glia), after ischemia-reperfusion, and were also increased in the in vitro model. The increased pAMPK in mouse brain was found not only in the region of the infarct, but also on the contralateral side where no infarct had occurred, indicating that the signal for AMPK activation is transmitted globally throughout the brain. Increasing AMPK activity would lead to inhibition of energy-using (anabolic) processes, which should conserve ATP. It would also activate energy-producing (catabolic) processes that make ATP. However, in stroke, the oxygen and glucose supply is cutoff. In a situation like this, is the increased AMPK activity of stroke really beneficial? We asked if decreasing AMPK activity pharmacologically would alleviate some of the detrimental effects of stroke. Pharmacological inhibition of AMPK by either C75, a known modulator of neuronal ATP levels, or Compound C reduced infarct volume dramatically. In contrast, activation of AMPK by AICAR exacerbated damage. 11 These data demonstrate a role for AMPK in the response of neurons during metabolic stress, and suggest that in ischemia, the activation of AMPK is deleterious. Furthermore, the data suggest that pharmacological inhibition of AMPK activity in the brain may be neuroprotective in stroke.
